絞り込み

17792

広告

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).

著者 Sugimoto T , Matsumoto T , Hosoi T , Miki T , Gorai I , Yoshikawa H , Tanaka Y , Tanaka S , Fukunaga M , Sone T , Nakano T , Ito M , Matsui S , Yoneda T , Takami H , Watanabe K , Osakabe T , Okubo N , Shiraki M , Nakamura T
Osteoporos Int.2014 Nov 18 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (288view , 0users)

Full Text Sources

Medical

Other Literature Sources

A 12-month extension phase of DIRECT in Japanese subjects with osteoporosis showed that total 3 years of denosumab treatment in Japanese postmenopausal women and men with osteoporosis was associated with low fracture rates, persistent bone turnover marker (BTM) reductions, continuous bone mineral density (BMD) increases, and a favorable overall benefit/risk profile.
PMID: 25403903 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード